Y-Mabs Therapeutics Inc (YMAB)’s Ratio Roundup: Key Metrics for Trailing Twelve Months

Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

As of close of business last night, Y-Mabs Therapeutics Inc’s stock clocked out at $13.61, down -20.92% from its previous closing price of $17.21. In other words, the price has decreased by -$20.92 from its previous closing price. On the day, 1.59 million shares were traded. YMAB stock price reached its highest trading level at $15.54 during the session, while it also had its lowest trading level at $12.9012.


To gain a deeper understanding of YMAB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.67 and its Current Ratio is at 6.15. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wedbush on May 10, 2023, Upgraded its rating to Outperform and sets its target price to $13 from $5 previously.

Morgan Stanley Downgraded its Equal-Weight to Underweight on January 27, 2023, while the target price for the stock was maintained at $4.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 05 ’24 when Gad Thomas sold 3,900 shares for $16.44 per share. The transaction valued at 64,116 led to the insider holds 158,700 shares of the business.

Rajah Vignesh sold 1,711 shares of YMAB for $28,283 on Mar 05 ’24. The SVP & CHIEF MEDICAL OFFICER now owns 33,889 shares after completing the transaction at $16.53 per share. On Mar 05 ’24, another insider, Smith Susan Laura, who serves as the SVP & CHIEF COMMERCIAL OFFICER of the company, sold 1,682 shares for $16.55 each. As a result, the insider received 27,837 and left with 33,918 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, YMAB now has a Market Capitalization of 597106048 and an Enterprise Value of 680135872. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.07 while its Price-to-Book (P/B) ratio in mrq is 6.02. Its current Enterprise Value per Revenue stands at 8.049 whereas that against EBITDA is -34.203.

Stock Price History:

The Beta on a monthly basis for YMAB is 0.75, which has changed by 0.7383839 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, YMAB has reached a high of $20.90, while it has fallen to a 52-week low of $4.60. The 50-Day Moving Average of the stock is -13.58%, while the 200-Day Moving Average is calculated to be 45.56%.

Shares Statistics:

It appears that YMAB traded 366.14K shares on average per day over the past three months and 266630 shares per day over the past ten days. A total of 43.67M shares are outstanding, with a floating share count of 33.18M. Insiders hold about 24.37% of the company’s shares, while institutions hold 53.41% stake in the company. Shares short for YMAB as of 1713139200 were 2328235 with a Short Ratio of 6.36, compared to 1710460800 on 2100314. Therefore, it implies a Short% of Shares Outstanding of 2328235 and a Short% of Float of 6.38.

Earnings Estimates

The performance of Y-Mabs Therapeutics Inc (YMAB) in the stock market is under the watchful eye of 5.0 analysts actively contributing to its current rating.On average, analysts expect EPS of -$0.14 for the current quarter, with a high estimate of -$0.11 and a low estimate of -$0.18, while EPS last year was -$0.15. The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.08 and low estimates of -$0.18.

Analysts are recommending an EPS of between -$0.34 and -$0.73 for the fiscal current year, implying an average EPS of -$0.46. EPS for the following year is -$0.28, with 5.0 analysts recommending between $0.02 and -$0.8.

Revenue Estimates

In the current quarter, 4 analysts expect revenue to total $19.93M. It ranges from a high estimate of $23.23M to a low estimate of $21.45M. As of the current estimate, Y-Mabs Therapeutics Inc’s year-ago sales were $20.25MFor the next quarter, 4 analysts are estimating revenue of $23.59M. There is a high estimate of $23.75M for the next quarter, whereas the lowest estimate is $23.3M.

A total of 7 analysts have provided revenue estimates for YMAB’s current fiscal year. The highest revenue estimate was $99.6M, while the lowest revenue estimate was $95.46M, resulting in an average revenue estimate of $97.16M. In the same quarter a year ago, actual revenue was $84.82MBased on 6 analysts’ estimates, the company’s revenue will be $118.27M in the next fiscal year. The high estimate is $133M and the low estimate is $110.4M.

Most Popular

[the_ad id="945"]